-
Views
-
Cite
Cite
Pegcetacoplan, American Journal of Health-System Pharmacy, Volume 78, Issue 19, 1 October 2021, Pages 1752–1754, https://doi.org/10.1093/ajhp/zxab267
- Share Icon Share
Extract
Pegcetacoplan is a complement inhibitor.
Class: 92:32 • Complement Inhibitors (AHFS primary)
Brands: Empaveli®
REMS
FDA approved a REMS for pegcetacoplan to ensure that the benefits outweigh the risk. The REMS may apply to one or more preparations of pegcetacoplan. See the FDA REMS page (http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm).
Uses
Pegcetacoplan has the following uses:
...
Dosage and Administration
General
Pegcetacoplan is available in the following dosage form(s) and strength(s):
...
Dosage
It isessentialthat the manufacturer’s labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Adults
Dosage and Administration
...
Cautions
Contraindications
Pegcetacoplan is contraindicated in:
...
Warnings/Precautions
Serious Infections Caused by Encapsulated Bacteria
The use of pegcetacoplan may predispose individuals to serious, life-threatening, or fatal infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis types A, C, W, Y, and B, and Haemophilus influenzae type B (Hib). To reduce the risk of infection, all patients must be vaccinated against these bacteria according to the most current ACIP recommendations for patients with altered immunocompetence associated with complement deficiencies. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with pegcetacoplan.
Comments